KIT and hepatocellular carcinoma: Lenvatinib is a small multi-TKI which works against VEGFR-1,-2, and -3, FGFR-1,-2,-3, and -4, PDGFRα, KIT, and (RET), approved on August 2018 by FDA for first-line treatment of unresectable HCC (100).